You are here


Human Synovial Sarcoma Cell Line A2243

Primary tabs

The National Cancer Institute (NCI) seeks parties interested in licensing a human synovial sarcoma cell line (A2243). This cell line is an excellent research tool to study synovial sarcoma with a focus on chromosome translocations.
NIH Reference Number
Product Type
  • Synovial Sarcoma, Human Cell Line, A2243, Chromosomal Translocation, Mesenchymal Cells, Connective Tissue, SYT, SSX, Tumor Formation, Rare Cancer, Drug Screening, Aaronson
Collaboration Opportunity
This invention is available for licensing.
Description of Technology

Synovial sarcoma is a cancer affecting mesenchymal cells in connective tissues. This rare cancer is typically linked to genetic abnormalities or exposure to radiation. Metastatic growth throughout the body can occur primarily through blood circulation. More than 90% of synovial sarcomas show a characteristic t(X;18)(p11;q11) translocation involving the SYT and SSX genes. The resulting SYT-SSX abnormal fusion protein causes misregulation of downstream gene expression, leading to tumor formation.

Researchers at the National Cancer Institute (NCI), Laboratory of Cellular and Molecular Biology (LCMB), have derived a cell line, A2243, from a patient with human synovial sarcoma. This cell line forms tumors in nude mice. The A2243 cell line has been used to characterize the abnormal karyotype associated with synovial sarcoma. Additionally, the A2243 cell line has been used to discover the gene involved in recurrent chromosomal translocation.

NCI is seeking parties to non-exclusively license the A2243 human synovial sarcoma cell line.

Potential Commercial Applications
  • Research tool for drug screening efforts
  • Research tool for identifying general and specific chromosomal translocations in synovial sarcoma


Competitive Advantages
  • Well-characterized cell line for a rare human cancer: synovial sarcoma



Stuart A Aaronson, Nelson Ellmore

Development Stage

Clark J, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma.  [PMID 7951320]

Patent Status
  • Research Material: NIH will not pursue patent prosecution for this technology
Therapeutic Area
Tuesday, May 25, 2021